Experienced in Autoimmune Hemolytic Anemia

Dr. David E. Kanamori

Ravi Patel M D Inc
Bakersfield, CA
Experienced
in Autoimmune Hemolytic Anemia
Specialties:Hematology | Oncology
OverviewInsuranceLocationsClinical Research

Overview

David Kanamori is a Hematologist and an Oncologist in Bakersfield, California. Dr. Kanamori and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Hemosiderosis, Idiopathic Pulmonary Hemosiderosis, Agranulocytosis, and Chronic Familial Neutropenia.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Specialist in CA
Hospital Affiliations
Bakersfield Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

RAVI PATEL M D INC
6501 Truxtun Ave, Bakersfield, CA 93309
661-322-2206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Study Phase: Phase 2
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 18, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
View 7 Less Clinical Trials

1 Total Publications

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Journal: Anti-cancer drugs
Published: March 16, 2019
Similar Doctors
Expertise in
1
conditions
Dr. Anwer Baloch
Hematology | Oncology
Expertise in
1
conditions
Dr. Anwer Baloch
Hematology | Oncology

State Of California - Department Of Developmental Services

26501 Ave, Suite 140, 
Porterville, CA 
 (47.4 mi)
559-782-2259
Languages Spoken:
English
See accepted insurances

Anwer Baloch is a Hematologist and an Oncologist in Porterville, California. Dr. Baloch and is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are RUNX1 Familial Platelet Disorder, Paget Disease of the Breast, Breast Cancer, and Hemangioma Thrombocytopenia Syndrome.

Expertise in
33
conditions
Dr. Kota C. Shekar
Hematology Oncology | Hematology | Oncology
Expertise in
33
conditions
Dr. Kota C. Shekar
Hematology Oncology | Hematology | Oncology

Ravi Patel M D Inc

6501 Truxtun Ave, 
Bakersfield, CA 
661-322-2206
Languages Spoken:
English
See accepted insurances

Kota Shekar is a Hematologist Oncology specialist and a Hematologist in Bakersfield, California. Dr. Shekar and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Pleuropulmonary Blastoma, Testicular Yolk Sac Tumor, Ovarian Cancer, and Ovarian Carcinosarcoma.

Expertise in
11
conditions
Dr. Samuel S. Kuo
Hematology Oncology | Geriatrics | Hematology
Expertise in
11
conditions
Dr. Samuel S. Kuo
Hematology Oncology | Geriatrics | Hematology

Altura Centers For Health

1101 N Cherry St, 
Tulare, CA 
 (61.3 mi)
559-686-9097
Languages Spoken:
English
See accepted insurances

Samuel Kuo is a Hematologist Oncology specialist and a Geriatrics provider in Tulare, California. Dr. Kuo and is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Anemia, Thrombocytopenia, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile